Rare Tumors最新文献

{"title":"A rare case report of a myxoid liposarcoma arising from the broad ligament.","authors":"Farah Sassi,&nbsp;Ghada Sahraoui,&nbsp;Lamia Charfi,&nbsp;Zemni Ines,&nbsp;Karima Mrad,&nbsp;Raoudha Doghri","doi":"10.1177/20363613221148839","DOIUrl":"https://doi.org/10.1177/20363613221148839","url":null,"abstract":"<p><p>Myxoid liposarcoma (MLPS) is the second most prevalent subtype of liposarcoma. It is usually found in the deep tissues of the lower limbs and rarely in gynecologic tract. Herein we present the second case in the English literature of a primary MLPS arising from the broad ligament which was thought to be a borderline ovarian tumor. The aim is to discuss its clinical and pathological characteristics. A 42-year-old woman presented with pelvic pain for the last 6 months. Magnetic resonance imaging was not specific. She underwent a surgical resection of the tumor mass, and pathological examination confirmed the diagnosis of MLPS deriving from the broad ligament. She received radiotherapy and the patient is doing well at 3 months follow-up. The clinical aspects, pathological diagnosis, prognosis, and therapy approach of broad ligament MLPS are all poorly understood. Complete surgical resection with or without radiotherapy is the mainstay of treatment in located MLPS.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"14 ","pages":"20363613221148839"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/05/10.1177_20363613221148839.PMC9793064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10446283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESSION OF CONCERN: The first case report of primary thyroid teratocarcinosarcoma: An analog to sinonasal teratocarcinosarcoma","authors":"","doi":"10.1177/20363613221101702","DOIUrl":"https://doi.org/10.1177/20363613221101702","url":null,"abstract":"[This corrects the article DOI: 10.1177/20363613211043662.].","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"14 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42188294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and paraclinical features, outcome, and prognosis of ovarian granulosa cell tumor: A retrospective study of 28 Vietnamese women.","authors":"Duc Thanh Le,&nbsp;Tu Anh Do,&nbsp;Linh Ly Thi Nguyen,&nbsp;Kien Hung Do,&nbsp;Chu Van Nguyen","doi":"10.1177/20363613221148547","DOIUrl":"https://doi.org/10.1177/20363613221148547","url":null,"abstract":"<p><p><b>Background:</b> Granulosa cell tumor of the ovary is a rare disease and presents with two clinically and molecularly distinct subtypes: the juvenile and the adult type. GCT is considered as a malignant tumor with an indolent course and a tendency toward late recurrence. <b>Purpose</b>: To assess the clinical and paraclinical features, treatment findings, survival outcomes, and explored the prognostic factors in the granulosa cell tumor. <b>Methods</b>: The current study was conducted on 28 GCT patients who had surgical operations and adjuvant chemotherapy (stage IC-IV) by applying a retrospective cohort analysis. The clinical and paraclinical characteristics were recorded. Recurrent status was evaluated for analysis with clinical and paraclinical features and survival. All GCT patients' survival were analyzed by using Kaplan-Meier and Log-Rank models. <b>Results</b>: 17.9% of patients experienced a relapse and two patients died due to disease. The mean time from initial diagnose to recurrence was 40.21 months. The 5-year OS and DFS of stage I-II were 100% and 80.8%, and of stage III were 50% and 25%, respectively. In survival analyses, using the log-rank test, age ≥50 years, irregular menstruation, stage I-II, and absence of residual lesion were all significant predictors for the improved DFS. Stage I-II and absence of residual lesion were associated significantly with better OS. Mean of age, FIGO stage, and residual lesion during surgery had significant differences to recurrent rate (p < <0.05). The multivariate model revealed that these factors didn't remain as an independent prognostic variable. <b>Conclusion</b>: FIGO stage and residual lesion during surgery had significant differences in survival and recurrent rate.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"14 ","pages":"20363613221148547"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/12/10.1177_20363613221148547.PMC9793063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10455193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title: Clinico-pathological and survival profiles of orbito-ocular tumors in Enugu Nigeria. Is there an emerging trend?","authors":"N. Uche, O. Okoye, O. Okoye, I. Oguegbu, E. Uche","doi":"10.1177/20363613221079763","DOIUrl":"https://doi.org/10.1177/20363613221079763","url":null,"abstract":"Background Orbito-ocular tumors are rare, but they cause significant morbidity and mortality. There are reported variations in their pattern of presentation and frequency of occurrence. Objective To evaluate the occurrence, clinico-pathologic spectrum, and patterns of orbito-ocular neoplasms as well as the treatment and outcome profiles. Methods A 5-year retrospective analysis of consecutive patients treated for orbito-ocular tumors. We evaluated patterns of occurrence, clinic-pathological concordance, and outcome of treatment. Associations were evaluated with chi square and confidence interval. Data analysis was performed using SPSS for windows version 23 and inferences were judged using the 95% level of significance. Results Among 100 patients with orbito-ocular masses, 62 were histologically confirmed. The female to male ratio (F:M) was 1.0. Their ages ranged from 7 months to 93 years, mean = 33.4 ± 2.7 years. There was an age variation among tumor types. Patients with squamous cell carcinoma (SCC) had a mean age of 46.4 years, while for retinoblastoma the mean age was 3.09 years. All patients with retinoblastoma had proven macroscopic orbital extension. SCC was the most common tumor type (n = 19), however, among children, retinoblastoma (n = 11) was more common. Melanocytic nevus, sebaceous gland carcinoma, and adenocarcinoma of lacrimal gland (n = 6, n = 5, n = 5), respectively, among other tumors were treated. Concordance between clinical and histopathological diagnoses was obtained among 30 (48.3%) cases. 1-year and 3-year survival for retinoblastoma was 90% and 72.9%, respectively, and 78.9% and 68.4% for SCC. Conclusion SCC is currently the most common orbito-ocular tumor in our setting.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43326354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial","authors":"B. V. Van Tine, A. Krarup-Hansen, L. Hess, A. A. Abdul Razak, V. Soldatenkova, Jennifer Wright, S. Park","doi":"10.1177/20363613221100033","DOIUrl":"https://doi.org/10.1177/20363613221100033","url":null,"abstract":"Background: Patient-reported outcomes (PROs), including health-related quality of life, are recommended to be routinely collected in clinical trials, but data are limited from trials of sarcoma patients. In this analysis, pooled PRO data are reported from patients with advanced or metastatic soft tissue sarcoma (STS) enrolled to the ANNOUNCE phase III trial of doxorubicin-based therapy. Methods: ANNOUNCE was a phase III trial that randomized 509 patients with STS to receive up to eight cycles of doxorubicin with olaratumab or placebo, followed by single-agent olaratumab or placebo. Dexrazoxane was allowed at any cycle of treatment. Participants completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30, which is scored 0–100), and Brief Pain Inventory Short Form Modified (mBPI-sf, scored from 0–10) at each treatment cycle. A descriptive analysis of the longitudinal data was conducted overall and by cumulative dose of doxorubicin received to inform the clinical care of patients with STS. Worsening on the QLQ-C30 was defined as a change of 10 points or more at any post-baseline assessment. Worsening on the mPBI-sf was defined as an increase of ≥2 points from baseline. Results: The majority of participants completed the baseline and at least one subsequent PRO assessment within the trial (n = 460, 90.4% EORTC QLQ-C30; n = 454, 89.2%, mBPI-sf). Patients with STS enrolled to the ANNOUNCE trial had clinically meaningful problems with physical function and pain before initiating doxorubicin. Overall, those with fewer symptoms or better function at baseline received higher cumulative doxorubicin dose throughout the study. At baseline, mean QLQ-C30 fatigue was 29.9 with a median time to first worsening of 0.9 months, and mean nausea/vomiting was 6.5 with 1.4 months until worsening; mean physical function was 78.3 with median time to worsening of 2.1 months and mean health status was 66.8 with median time to first worsening of 1.6 months. Median time to worsening of pain was 7.9 months. Conclusion: Patients with advanced or metastatic sarcoma reported a relatively rapid decline in PROs during doxorubicin-based treatment, with patients with poorer symptoms at baseline (specifically fatigue), subsequently receiving less doxorubicin therapy. The availability of detailed summary data from the patient perspective during doxorubicin-based treatment may inform future care of these patients and can provide a resource for the development of PRO endpoints in future trials.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47755898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polymorphous low-grade neuroepithelial tumor of the young: Rare tumor and review of the literature","authors":"Ali H. Palejwala, Christen M. O’Neal, Michael R Quinton, J. Battiste, J. Peterson, I. Dunn","doi":"10.1177/20363613221083360","DOIUrl":"https://doi.org/10.1177/20363613221083360","url":null,"abstract":"Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a recently described low-grade neuroepithelial tumor with an infiltrative growth pattern and oligodendrocyte-like cells that are CD34 immunopositive. Correlating histology and results from molecular testing is critical to correctly diagnosing PLNTY, as its histologic appearance is similar to oligodendrogliomas and shares genetic abnormalities common to other low-grade epilepsy associated tumors (LEATs). In this case report, we describe a 31-year-old female with intractable epilepsy found to have a temporal mass and diagnosed with PLNTY after histopathologic and molecular testing. We describe the radiographic, histologic, and genetic features in relation to the epileptic and oncologic outcomes for this patient. Then, we compare these features and outcomes to other cases of PLNTY described in the literature.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43570520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric adenocarcinoma of the fundic gland: A review of clinicopathological characteristics, treatment and prognosis.","authors":"Xiang-Yu Meng,&nbsp;Guang Yang,&nbsp;Cheng-Ji Dong,&nbsp;Ru-Yi Zheng","doi":"10.1177/20363613211060171","DOIUrl":"https://doi.org/10.1177/20363613211060171","url":null,"abstract":"<p><p>Gastric adenocarcinoma of the fundic gland is a rare, well-differentiated gastric cancer entity, and very few patients transition to poorly differentiated tubular adenocarcinoma during progression. Gastric adenocarcinoma of the fundic gland originates from the mucosa of the gastric fundic gland, usually without chronic gastritis or intestinal metaplasia. Histologically, the tumor cells are closely arranged to form anastomosing tubular glands, and more than 95% of tumor cells differentiate towards chief cells. Most gastric adenocarcinoma of the fundic gland cases are characterized by submucosal involvement, but the tumor volume is usually small, with lymphatic and vascular invasion rarely observed. Therefore, endoscopic submucosal dissection can be an ideal treatment, leading to a favorable prognosis, and recurrence and metastasis of the disease are uncommon.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613211060171"},"PeriodicalIF":0.9,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/33/10.1177_20363613211060171.PMC8679019.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39739295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The challenge to differentiate between sarcoma or adrenal carcinoma-an observational study.","authors":"Eva M Dobrindt,&nbsp;Wolfgang Saeger,&nbsp;Hendrik Bläker,&nbsp;Martina T Mogl,&nbsp;Marcus Bahra,&nbsp;Johann Pratschke,&nbsp;Nada Rayes","doi":"10.1177/20363613211057746","DOIUrl":"https://doi.org/10.1177/20363613211057746","url":null,"abstract":"<p><strong>Background: </strong>Adrenal sarcomas are rare malignant tumors with structural and clinical similarities to sarcomatoid adrenocortical carcinoma. Preoperative diagnosis of tumors of the adrenal gland can be challenging and often misleading thus detaining patients from appropriate oncological strategies.</p><p><strong>Objective: </strong>This analysis of a case series evaluated the predictive capability of the primary clinical diagnosis in case of malignancies of the adrenal gland.</p><p><strong>Methods: </strong>Thirty two patients were treated from 2009 to 2015 at our clinic and analyzed retrospectively. All patients had computed tomography and/or magnet resonance imaging and a primary histopathological examination at our institution after surgery. Ten questionable cases were surveyed by a reference pathologist.</p><p><strong>Results: </strong>Twelve out of 32 diagnoses had to be revised (37.5%). Only 15 out of 24 tumors primarily classified as adrenocortical carcinoma were finally described as primary adrenal cancer. We found two leiomyosarcomas, one liposarcoma, one sarcomatoid adrenocortical carcinoma, and one epitheloid angiosarcoma among 12 misleading diagnoses. Other tumors turned out to be metastases of lung, hepatocellular, and neuroendocrine tumors. Larger tumors were significantly more often correctly diagnosed compared to smaller tumors. Four patients of the group of revised diagnoses died whereas all patients with confirmed diagnoses survived during the follow-up.</p><p><strong>Conclusion: </strong>Preoperative assessment of tumors of the adrenal gland is still challenging. In case of wrong primary diagnosis, the prognosis could be impaired due to inadequate surgical procedures or insufficient preoperative oncological treatment.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613211057746"},"PeriodicalIF":0.9,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/7f/10.1177_20363613211057746.PMC8669116.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39821737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the role of indoleamine-2,3-dioxygenase and stromal differentiation in rare subtype endometrial cancer.","authors":"Dongling Wu,&nbsp;Sean Hacking,&nbsp;Jin Cao,&nbsp;Mansoor Nasim","doi":"10.1177/20363613211044690","DOIUrl":"https://doi.org/10.1177/20363613211044690","url":null,"abstract":"<p><p>Endometrial cancer (EC) is a disease with good and poor prognostic subtypes. Dedifferentiated endometrial carcinoma (DEC), undifferentiated endometrial carcinoma (UEC), and clear cell endometrial carcinoma (CEC) are rare high-grade tumors, associated with a poor prognosis and high pathologic stage. Many studies have been performed on the programmed death-ligand 1 (PD-L1) axis mainly focus on endometrioid adenocarcinomas and little research has been done on rare subtypes. The present body of work aims to evaluate the role of indoleamine-2,3-dioxygenase (IDO-1) and stromal differentiation (SD), their correlation with clinicopathologic features and overall survival. Here we found that positive IDO-1 expression in immune cells correlated with worse disease-free survival (<i>p</i> = 0.02), recurrence (<i>p</i> = 0.03), high pathologic tumor stage (<i>p</i> = 0.024), lymph node metastasis (<i>p</i> = 0.028), and myometrial invasion (<i>p</i> = 0.03). Our findings suggest IDO-1 to be relevant in both MMR intact and deficient tumors; however, >20% immune cell staining was restricted to MMR deficient cancers. For the stroma, immature, myxoid differentiation was found to correlate with worse disease-free survival (<i>p</i> = 0.04). We also found the correlation between IDO-1 expression and immature stroma. Looking forward, IDO-1 could be promising for immunotherapy and SD could be the answer to clinical heterogeneity.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613211044690"},"PeriodicalIF":0.9,"publicationDate":"2021-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/45/10.1177_20363613211044690.PMC8655461.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39719293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National advisory panels for paediatric cancer in the UK as an example of rare cancer multidisciplinary team meetings.","authors":"S Brown,&nbsp;J Bate","doi":"10.1177/20363613211052503","DOIUrl":"https://doi.org/10.1177/20363613211052503","url":null,"abstract":"Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). We recognise the proposed advantages of multidisciplinary team (MDT) working that Rosell et al.1 describe in their evaluation paper. In the UK, multidisciplinary team (MDT) working is mandated in the National Health Service (NHS) Cancer Plan. Benefits of this model include improved evidence-based treatment decisions, coordination of care and education for MDT members, along with improved patient outcomes and clinical trial recruitment.2–5 Childhood cancer is rare. There are approximately 1900 new cases per year in the UK, with childhood cancer cases comprising less than 1% of all new cancer cases.6 All children with suspected cancer in the UK are referred to one of 19 principle treatment centres (PTC) which together comprise a network of tertiary specialist cancer services for diagnosis, treatment and coordination of care for each patient. It is standard of care for every child with a new diagnosis to be discussed at a PTC MDT meeting at which recommendations are formulated for management. In addition to PTC MDT meetings, there has been a recent rise in a number of virtual national advisory panels (NAP) for children’s cancer in the UK. These panels have developed alongside increasing centralisation of cancer services and enhanced complexities of patient management. Advice may be sought from these panels for individual patients with specific disease types including sarcoma (panel established in 2011), histiocytosis (2013), ependymoma (2015) leukaemia (2016), neuroblastoma (2017) and renal cancers (2017) As of January 2019, collectively there had been 920 referrals to the NAPs in the UK. Rosell et al. acknowledge rare cancers and complex cases may benefit from referrals to such forums to gather further clinical expertise, particularly when the evidence base is lacking or treatment pathway is not clearly defined. In contrast to the Swedish model described in Rosell’s evaluation, NAP referral is not mandated at either diagnosis or relapse. Furthermore, NAPs are distinct from PTC MDT meetings, involving national experts for particular cancer types offering an advisory role only ensuring overall responsibility for the patient remains that of the referring team. While the primary role of the NAPs is not to ensure equitable access to treatment, there is a degree of overlap with the UK Experimental Cancer Medicine Network regional meetings (ECMC). These meetings are designed to discuss cases at time of relapse to ensure equitable access to clinical trials, irrespective of geography. In contrast to the NAPs, it is an","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613211052503"},"PeriodicalIF":0.9,"publicationDate":"2021-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/93/10.1177_20363613211052503.PMC8559199.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39588927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}